研究单位：[1]Chinese Academy of Medical Sciences[2]Genor Biopharma Co., Ltd.[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China,233099[4]Anhui Provincial Cancer Hospital,Hefei,Anhui,China,230031[5]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230601[6]Beijing Chaoyang Hospital of Capital Medical University,Beijing,Beijing,China,100020[7]Cancer hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[8]Chinese PLA General Hospital,Beijing,Beijing,China,100039[9]Beijing Tiantan Hospital , Capital Medical University,Beijing,Beijing,China,100050[10]Chongqing University Cancer Hospital,Chongqing,Chongqing,China,400030[11]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400042[12]Chognqing University Three Gorges Hospital,Chongqing,Chongqing,China,404000[13]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[14]First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361003[15]The First people's hospital of Foshan,Foshan,Guangdong,China,528000[16]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[17]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510080[18]Guangdong provincial TCM hospital,Guangzhou,Guangdong,China,510120[19]Meizhou People's Hospital,Meizhou,Guangdong,China,514031[20]Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center Shenzhen Cancer Hospital,Shenzhen,Guangdong,China,518172[21]Hainan General Hospital,Haikou,Hainan,China,570311[22]Hainan Third People's Hospital,Sanya,Hainan,China,572000[23]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,50011[24]Affiliated hospital of Hebei University,Shijiazhuang,Hebei,China,500311[25]Harbin Medcial Univercity cancer hospital,Haerbin,Heilongjiang,China,150081[26]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[27]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[28]Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[29]Renmin Hospital of Wuhan University,Wuhan,Hubei,China,430060[30]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[31]The Affiliated hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China,750306[32]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[33]Jiangxi Provincial Hospital,Nanchang,Jiangxi,China,330029[34]Jilin Cancer Hospital,Changchun,Jilin,China,130012[35]The Second Hospital of Jilin University,Changchun,Jilin,China,130041[36]Bethune First Hospital Of Jilin University,Changchun,Jillin,China,130061[37]Shengjing Hospital of China Medical University,Shenyang,Liaoning,China,110022[38]Liaoning Cancer hospital & Institute,Shenyang,Liaoning,China,110801[39]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China,750003[40]Central Hospital Affiliated to Shandong First Medical University,Jinan,Shandong,China,250013[41]Shandong Provincial Qianfoshan Hospital,Jinan,Shandong,China,250013[42]Shandong Provincial Hospital,Jinan,Shandong,China,250021[43]Shandong Cancer Hospital,Jinan,Shandong,China,250117[44]Affiliated hospital of Jining Medical University,Jining,Shandong,China,272007[45]Liaocheng People's Hospital,Liaocheng,Shandong,China,252004[46]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266003[47]Taian City Central Hospital,Taian,Shandong,China,271099[48]Yantai Yuhuangding Hospital,Yantai,Shandong,China,264099[49]Zhongshan Hospital Fudan University,Shanghai,Shanghai,China,200030[50]The first hospital of Shanxi Medical University,Taiyuan,Shanxi,China,003001[51]West China School of Medicine,Chengdu,Sichuan,China,610044[52]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China,300181[53]Affiliated Cancer Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China,830011[54]The Third Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650118
GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.
